Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19406113 | 0.88 | CCR2 (0.73) | CCR2PKMBRAFMEN1KMT2A | |
| SCHEMBL9930917 | 0.87 | CCR2 (0.76) | CCR2PKMBRAFMEN1LMNA | |
| SCHEMBL9930692 | 0.85 | CCR2 (0.78) | CCR2PKMBRAFMEN1LMNA | |
| SCHEMBL9930779 | 0.85 | CCR2 (0.73) | CCR2PKMBRAF | |
| SCHEMBL9931058 | 0.85 | CCR2 (0.77) | CCR2PKMBRAFMEN1LMNA | |
| SCHEMBL9930868 | 0.85 | CCR2 (0.73) | CCR2PKMBRAFMEN1KMT2A | |
| SCHEMBL9931071 | 0.84 | CCR2 (0.68) | CCR2MEN1KMT2A | |
| SCHEMBL28231611 | 0.84 | CCR2 (0.68) | CCR2PKMBRAFMEN1LMNA | |
| SCHEMBL9930749 | 0.84 | CCR2 (1.00) | CCR2PKMBRAFMEN1LMNA | |
| SCHEMBL9931955 | 0.84 | CCR2 (0.71) | CCR2PKMBRAFMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012082633-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |